Status:
UNKNOWN
External Validation of the CHOD Risk Scale
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conditions:
COVID-19 Pneumonia
Pulmonary Embolism
Eligibility:
All Genders
18+ years
Brief Summary
Severe COVID-19 is associated with a hypercoagulable state, with a high risk of thrombotic phenomena such as pulmonary thromboembolism (PE). Its diagnostic suspicion is complicated, due to the overlap...
Eligibility Criteria
Inclusion
- Diagnostic confirmation of SARS-CoV-2 infection by positive result in at least one test:
- Rapid nasopharyngeal smear antigen test.
- PCR smear or nasopharyngeal aspirate.
- Sputum PCR.
- PCR of bronchoalveolar lavage.
- Positive IgM in the serology for SARS-CoV2
- Hospitalization for COVID-19 pneumonia
- More than 5 days from the date of onset of symptoms (this criterion can be met during hospitalization).
- Elevated D-dimer, by any of the following criteria:
- DD\> 500 ng/ml; In the case of patients over 50 years of age, the DD cut-off point adjusted for age (age x 10) will be applied.
- With the DDU measurement, the cut-off point is 250 mg/dl (instead of 500) and the adjustments for age in those over 50 years are made by multiplying the age x 5 (instead of x 10).
Exclusion
- Pregnancy.
- Age \<18 years.
- Hemodynamic instability: SBP \<90 mmHg or vasopressors to achieve ≥ 90 mmHg.
- Contraindication for performing CT angiography:
- Severe kidney failure (GFR \<30)
- Allergy to iodinated contrasts.
- Intolerance to decubitus.
Key Trial Info
Start Date :
May 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT04889261
Start Date
May 17 2021
End Date
December 31 2021
Last Update
May 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08041